Clinical trial
A Phase Ib Age De-escalation and Dose Escalation Open Label Clinical Trial of the Safety, Immunogenicity and ex Vivo Efficacy of a Candidate Malaria Vaccine Pfs25-IMX313/Matrix-M Administered Intramuscularly in Healthy Adults and Young Children in Tanzania.
NCT04271306 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib Age De-escalation and Dose Escalation Open Label Clinical Trial of the Safety, Immunogenicity and ex Vivo Efficacy of a Candidate Malaria Vaccine Pfs25-IMX313/Matrix-M Administered Intramuscularly in Healthy Adults and Young Children in Tanzania.
- Lead sponsor
- University of Oxford
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- May 25, 2021
- Completion date
- February 19, 2024
- Enrollment
- 34 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
malaria,falciparum